Trial reportCancer biology & medicine2020
Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
Open access · goldAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
In one paragraph
Trial report in Cancer biology & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 45 citations in OpenAlex.
- Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial.Cancer biology & medicine · 2024Trial
- Primary leiomyosarcoma of the lumbar soft tissue treated with multimodal therapy, including anlotinib: A case report.Oncology letters · 2026Article
- Neoadjuvant therapy with anlotinib in a 5-year-old child with advanced papillary thyroid carcinoma: a case report.Frontiers in pediatrics · 2026Article
- Inhibitory effect of the multi-target TKI, anlotinib, in 5-FU resistant colorectal cancer HCT-8/15 cells: down regulation of drug resistance-associated protein expression.Frontiers in oncology · 2026Article
- Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives.Cancer chemotherapy and pharmacology · 2025Review
- Efficacy and safety of anlotinib plus EGFR tyrosine kinase inhibitors in slow- or locally progressing non-small cell lung cancer after adjuvant therapy.Translational lung cancer research · 2025Article
- Off-label use of anlotinib in malignancies' treatment: efficacy and management of adverse reactions.Pharmacological reports : PR · 2025Review
- PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib.Frontiers in oncology · 2025Article
- [Aumolertinib combined with anlotinib inhibits proliferation of non-small cell lung cancer cells by down-regulating the PI3K/AKT pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Homodimeric peptide radiotracer [European journal of nuclear medicine and molecular imaging · 2024Article
- Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progression.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Anti-lymphangiogenesis for boosting drug accumulation in tumors.Signal transduction and targeted therapy · 2024Article
- Antineoplastic indole-containing compounds with potential VEGFR inhibitory properties.RSC advances · 2024Review
- Lymphatic vessel: origin, heterogeneity, biological functions, and therapeutic targets.Signal transduction and targeted therapy · 2024Review
- Case report of severe pneumothorax due to lung cancer treated with anlotinib.The Journal of international medical research · 2023Article
- Lymphangiogenesis in gastric cancer: function and mechanism.European journal of medical research · 2023Review
- Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring TERT promoter and BRAFArchives of endocrinology and metabolism · 2023Article
- An Analysis of the Gene Expression Associated with Lymph Node Metastasis in Colorectal Cancer.International journal of genomics · 2023Article
- Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis.Journal of clinical medicine · 2022Article
- Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Tingting QinDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Zhujun LiuDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Jing WangDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Junling XiaDepartment of Biomedical Engineering, Tianjin Medical University, Tianjin 300070, China.
Shaochuan LiuDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Yanan JiaDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Hailin LiuDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Kai LiDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.ORCID 0000-0002-6895-0024
Tianjin Medical University Cancer Institute and Hospital · CNNational Clinical Research · USTianjin Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
A549 CellsAdenocarcinoma of LungAdolescentAdultAgedAnimalsDouble-Blind MethodFemaleHumansIndolesLung NeoplasmsLymphangiogenesisLymphatic MetastasisMaleMiceMice, Inbred BALB CanlotinibIndolesQuinolinesVascular Endothelial Growth Factor Receptor-3Anlotiniblung adenocarcinomalymphangiogenesislymph node metastasisVEGFR-3 dephosphorylation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.